TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25632203

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 66
Study: 23527715

Group type: EXPERIMENTAL
Intervention: 9 mg sodium hyaluronate
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 75
Study: 21720259

Group type: EXPERIMENTAL
Intervention: Cues program
Number of subjects: 121

Group type: COMPARATOR
Intervention: Care (attention control)
Number of subjects: 121
Study: 19491816

Group type: EXPERIMENTAL
Intervention: Velaxin (venlafaxine) 75 mg daily for 8 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no antidepressants or antiepileptics)
Number of subjects: 47
Study: 16947783

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment (up to 25 mg per week orally) combined with folic acid
Number of subjects: 205
Study: 12929065

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) using propofol and alfentanil
Number of subjects: 67

Group type: COMPARATOR
Intervention: Midazolam and pethidine
Number of subjects: 67
Study: 10849058

Group type: EXPERIMENTAL
Intervention: Cinnamon extract (40 mg twice daily for 4 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9111403

Group type: EXPERIMENTAL
Intervention: Patellar replacement during total knee arthroplasty
Number of subjects: 26

Group type: COMPARATOR
Intervention: No patellar replacement during total knee arthroplasty
Number of subjects: 26
Study: 8462917

Group type: COMPARATOR
Intervention: Tannacomp (500 mg of tannin albuminate and 50 mg ethacridine lactate), administered as 2 tablets three times a day for 5 days, followed by 5 days without treatment, then another 5 days of the same regimen.
Number of subjects: 30
Study: 3517701

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 300 mg per diem for 14 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Indomethacin 150 mg per diem for 14 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 16

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 16
Study: 30194992

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg weekly for 16 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 54
Study: 29097122

Group type: EXPERIMENTAL
Intervention: FT+TMP gel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FT+Acid gel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FT+9000 gel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FT
Number of subjects: 12

Group type: COMPARATOR
Intervention: PT
Number of subjects: 12
Study: 27044884

Group type: EXPERIMENTAL
Intervention: Linear extrapolation (LE)
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Last observation carried forward (LOCF)
Number of subjects: 918
Study: 23417668

Group type: EXPERIMENTAL
Intervention: Triple P (Positive Parenting Program)
Number of subjects: 280

Group type: COMPARATOR
Intervention: No parenting intervention (control)
Number of subjects: 280
Study: 22356267

Group type: EXPERIMENTAL
Intervention: Selenomethionine (Seme) 200μg daily for 3 months (Se3), n = 15
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Selenomethionine (Seme) 200μg daily for 6 months (Se6), n = 46
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (Control), n = 25
Number of subjects: 86
Study: 20378225

Group type: EXPERIMENTAL
Intervention: Deliberative democracy sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study: 17875253

Group type: EXPERIMENTAL
Intervention: Healthy Children, Strong Families intervention promoting healthy eating and physical activity; details on dosage and duration not specified.
Number of subjects: 0
Study: 15895312

Group type: EXPERIMENTAL
Intervention: 200 microg salbutamol (SAL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 microg ipratropium bromide (IPR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study: 11553197

Group type: EXPERIMENTAL
Intervention: Nasal insulin (three preprandial doses combined with one evening subcutaneous NPH if needed)
Number of subjects: 10

Group type: COMPARATOR
Intervention: NPH injections (two daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nasal insulin
Number of subjects: 10
Study: 9605365

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 28
Study: 7989953

Group type: COMPARATOR
Intervention: Single-dose NSAIDs
Number of subjects: 1545

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1545

Group type: EXPERIMENTAL
Intervention: Low- and high-dose NSAIDs
Number of subjects: 1545

Group type: EXPERIMENTAL
Intervention: Recommended and supramaximal single doses of three NSAIDs
Number of subjects: 1545

Group type: COMPARATOR
Intervention: Weak opioids (WO) alone or in combination (WO/C) with nonopioid analgesics
Number of subjects: 1545

Group type: COMPARATOR
Intervention: Single doses of WO/C analgesics
Number of subjects: 1545

Group type: EXPERIMENTAL
Intervention: Multiple doses of NSAIDs
Number of subjects: 1545
Study: 3171371

Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with adrenaline 1 in 200,000
Number of subjects: 18

Group type: COMPARATOR
Intervention: Prilocaine 3% with felypressin 0.03 international units/ml
Number of subjects: 18
Study: 29794759

Group type: EXPERIMENTAL
Intervention: Chrisofix Chest Orthosis (CCO)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ER splint
Number of subjects: 24
Study: 27145364

Group type: EXPERIMENTAL
Intervention: (S)-citalopram AUC(0,24 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (R)-citalopram AUC(0,24 h)
Number of subjects: 0
Study: 24724835

Group type: EXPERIMENTAL
Intervention: Topical benzocaine
Number of subjects: 21

Group type: COMPARATOR
Intervention: No benzocaine (control)
Number of subjects: 21
Study: 22744627

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metformin administration
Number of subjects: 24
Study: 20334685

Group type: COMPARATOR
Intervention: LBC at entry and two years, combined LBC and hr-HPV at four years among those with initial negative results and hr-HPV triage of ASCUS cases (Control Arm)
Number of subjects: 33000

Group type: EXPERIMENTAL
Intervention: hr-HPV at entry and LBC at two years in those with initial negative results with LBC triage of hr-HPV positives (Two Year Safety Check Arm)
Number of subjects: 33000

Group type: EXPERIMENTAL
Intervention: hr-HPV at entry and combined hr-HPV and LBC at four years among those with initial negative results with LBC triage of hr-HPV positive cases (Four Year Intervention Arm)
Number of subjects: 33000
Study: 17461735

Group type: EXPERIMENTAL
Intervention: Non-antiarrhythmic drugs (beta-blockers, aldosterone antagonists, ACE inhibitors, angiotensin receptor-blockers, statins, omega-3 fatty acids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-antiarrhythmic drugs
Number of subjects: 0
Study: 15655123

Group type: EXPERIMENTAL
Intervention: Losartan intervention
Number of subjects: 8206

Group type: COMPARATOR
Intervention: Low baseline/low year 1 UACR
Number of subjects: 8206

Group type: COMPARATOR
Intervention: Low baseline/high year 1 UACR
Number of subjects: 8206

Group type: COMPARATOR
Intervention: High baseline/low year 1 UACR
Number of subjects: 8206

Group type: COMPARATOR
Intervention: High baseline/high year 1 UACR
Number of subjects: 8206

Group type: EXPERIMENTAL
Intervention: Components of primary composite endpoint (cardiovascular mortality, stroke, myocardial infarction)
Number of subjects: 8206
Study: 11854676

Group type: EXPERIMENTAL
Intervention: IPS Empress crowns luted with Variolink II low-viscosity resin cement and Syntac Classic dentin adhesive
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IPS Empress crowns luted with Variolink II and Syntac Single Component
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crowns with subgingival margin finish lines
Number of subjects: 20
Study: 10378327

Group type: EXPERIMENTAL
Intervention: Anticoagulation of unspecified duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proximal deep vein thrombosis or symptomatic pulmonary embolism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Permanent or unknown triggering factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of proximal deep vein thrombosis or symptomatic pulmonary embolism and permanent/unknown triggering factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of cardiolipin antibodies
Number of subjects: 0
Study: 8891761

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2066757

Group type: EXPERIMENTAL
Intervention: Immediate adjuvant chemotherapy
Number of subjects: 113

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Surgery and adjuvant chemotherapy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Surgical disease-free after initial relapse
Number of subjects: 113
Study: 6133575

Group type: EXPERIMENTAL
Intervention: Imaginal desensitization
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aversion-relief therapy
Number of subjects: 20
Study: 31347669

Group type: EXPERIMENTAL
Intervention: Diets with varying nutrient compositions (16 diets)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Validation experiment with 2 diets
Number of subjects: 48
Study: 30113559

Group type: EXPERIMENTAL
Intervention: Sequential bilateral cochlear implantation with a 2‐year interimplant interval
Number of subjects: 16
Study: 26955768

Group type: EXPERIMENTAL
Intervention: Succinylcholine administration during rapid sequence induction (RSI) for general anesthesia
Number of subjects: 30
Study: 25088394

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU per day)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 22248711

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (single subcutaneous injection at day 5)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Filgrastim (daily injections from day 5 until recovery of ANC to 0.5 G/L)
Number of subjects: 151
Study: 19439949

Group type: EXPERIMENTAL
Intervention: Conventional dentifrice (1,100 microg F/g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-F dentifrice (500 microg F/g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-F dentifrice (negative control)
Number of subjects: 0
Study: 17617747

Group type: EXPERIMENTAL
Intervention: Ranolazine 1000 mg bid
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Ranolazine 750 mg or 1000 mg bid
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study: 16172458

Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 355

Group type: COMPARATOR
Intervention: Stanford V
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: MOPPEBVCAD
Number of subjects: 355
Study: 11205198

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5 FU) alone (arm A: 450 mg/m2/day‐5/21 days)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Combined folinic acid (FOL) and 5 FU (arm B: 200 mg/m2 racemic form or 100 mg/m2‐l‐form and 370 mg/m2/day‐5/21 days)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: 5 FU alone (arm A)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Combined FOL and 5 FU (arm B)
Number of subjects: 366
Study: 9315984

Group type: EXPERIMENTAL
Intervention: Phenytoin (200 mg a.m. and 100 mg p.m.)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 60
Study: 8417635

Group type: EXPERIMENTAL
Intervention: Gallstone disease
Number of subjects: 383

Group type: COMPARATOR
Intervention: Normal gallbladders
Number of subjects: 383
Study: 3948628

Group type: EXPERIMENTAL
Intervention: Octylonium bromide (80 mg, qid, per os) for 5-7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: IBS patients (without treatment)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gastric emptying
Number of subjects: 20
Study: 3365885

Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty
Number of subjects: 34

Group type: COMPARATOR
Intervention: Open reduction
Number of subjects: 34
Study: 31132664

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 40 mg/mL three times weekly (GA40)
Number of subjects: 861

Group type: COMPARATOR
Intervention: Glatiramer acetate 20 mg/mL once daily (GA20)
Number of subjects: 861
Study: 28976536

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening (FS) at baseline and at 3 or 5 years
Number of subjects: 154900

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154900
Study: 26160608

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg/day
Number of subjects: 79

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 79
Study: 23218817

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% gel
Number of subjects: 406

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 406
Study: 21253774

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (individually adapted supplements enriched with protein and antioxidants)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (unsupplemented)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nutritional supplementation and Control
Number of subjects: 23
Study: 18460217

Group type: EXPERIMENTAL
Intervention: Parents' Evaluation of Developmental Status (PEDS) screening
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Referral for assessment
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Risk factors for delay
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Predicted probability of high risk screening
Number of subjects: 791
Study: 16507859

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 81 mg once daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 12735583

Group type: EXPERIMENTAL
Intervention: Fibrin glue (5 mL delivered by aerosolized spraying)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no additional intervention)
Number of subjects: 100
Study: 11054621

Group type: EXPERIMENTAL
Intervention: Carvedilol (long-term treatment, 4 months)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Carvedilol (long-term treatment)
Number of subjects: 29
Study: 9076868

Group type: COMPARATOR
Intervention: Gabapentin 400 mg T.I.D. for 48 hours
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Gabapentin higher doses (up to 3600 mg/day) during open-label extension
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg T.I.D. and 800 mg T.I.D.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8398955

Group type: EXPERIMENTAL
Intervention: 24-gauge Sprotte needle
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: 25-gauge Quincke needle
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Sprotte with fentanyl (n = 47)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Sprotte without fentanyl (n = 49)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Quincke with fentanyl (n = 49)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Quincke without fentanyl (n = 49)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Epidural blood patch therapy
Number of subjects: 194

Group type: COMPARATOR
Intervention: Fentanyl as adjunct
Number of subjects: 194
Study: 3533203

Group type: EXPERIMENTAL
Intervention: Blood transfusion (at least 2 units within 24 hours after admission)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No blood transfusion unless hemoglobin fell below 8 g/dl or patients were shocked (control group)
Number of subjects: 75
Study: 31359832

Group type: EXPERIMENTAL
Intervention: Apalutamide
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study: 28071330

Group type: EXPERIMENTAL
Intervention: Peginterferon β‐1a
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Patient education about ISR potential
Number of subjects: 37
Study: 26270625

Group type: EXPERIMENTAL
Intervention: 37.5 IU kg(‐1) PCC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 25 IU kg(‐1) PCC
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 23686969

Group type: EXPERIMENTAL
Intervention: Cognitive–behavioral therapy
Number of subjects: 114
Study: 21458721

Group type: EXPERIMENTAL
Intervention: Surgery (major ablative and reconstructive procedures)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Resting testosterone levels
Number of subjects: 5
Study: 18486703

Group type: EXPERIMENTAL
Intervention: Burr hole drainage with irrigation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Burr hole drainage without irrigation
Number of subjects: 82
Study: 17144124

Group type: EXPERIMENTAL
Intervention: Indomethacin (usual doses)
Number of subjects: 126
Study: 14513073

Group type: EXPERIMENTAL
Intervention: Fat-substituted diet (FS) containing olestra (33% lipid and 25% digestible fat)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control diet (33% fat)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Fat-reduced diet (FR; 25% fat)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: All groups (including FS, FR, and control)
Number of subjects: 37
Study: 10904510

Group type: EXPERIMENTAL
Intervention: Active treatment (12.5 mg/d of chlorthalidone, with possible addition of 25 mg/d of atenolol or 0.05 mg/d of reserpine)
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 4736
Study: 9054818

Group type: EXPERIMENTAL
Intervention: Children with hyperlipidemia (case subjects)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Children in the cross-sectional component
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Mothers of children with hyperlipidemia
Number of subjects: 52

Group type: COMPARATOR
Intervention: Mothers of children in the control group
Number of subjects: 52
Study: 8439209

Group type: EXPERIMENTAL
Intervention: 3 g ampicillin-sulbactam (2 g ampicillin-1 g sulbactam), every 6 hours
Number of subjects: 385

Group type: COMPARATOR
Intervention: 2 g cefoxitin, every 6 hours
Number of subjects: 385
Study: 3712636

Group type: EXPERIMENTAL
Intervention: Protamine (0.75 mg/kg/3 min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline solution (n = 8)
Number of subjects: 15
Study: 31596971

Group type: EXPERIMENTAL
Intervention: Team handball training without prior experience (UN)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Team handball training with prior experience (EXP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Inactive control group (CON)
Number of subjects: 32
Study: 29931180

Group type: EXPERIMENTAL
Intervention: Quantitative clinical staging model comprising VolCT and Fmax
Number of subjects: 472

Group type: COMPARATOR
Intervention: cTNM staging
Number of subjects: 472
Study: 28039798

Group type: EXPERIMENTAL
Intervention: Nicotine patches (5-week supply)
Number of subjects: 500
Study: 25583272

Group type: EXPERIMENTAL
Intervention: Self-care education program
Number of subjects: 378
Study: 24005123

Group type: EXPERIMENTAL
Intervention: Continuation phase cognitive therapy (C‐CT)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 241

Group type: COMPARATOR
Intervention: Pill placebo (PBO)
Number of subjects: 241
Study: 19940798

Group type: EXPERIMENTAL
Intervention: CTI + EI without the aid of fluoroscopy
Number of subjects: 53

Group type: COMPARATOR
Intervention: CTI
Number of subjects: 53
Study: 18431480

Group type: EXPERIMENTAL
Intervention: Intradermal vaccination with live attenuated yellow fever 17D vaccine at a reduced dose (1/5th; 0.1 mL)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Subcutaneous vaccination with live attenuated yellow fever 17D vaccine (0.5 mL)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: In previously vaccinated individuals
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Viraemia measurement
Number of subjects: 175
Study: 17205821

Group type: EXPERIMENTAL
Intervention: Resolving phlegm method (RPM) using Chinese herbs (Indigo Naturalis 10 g, Alumen 3 g, Semen Cassiae 15 g, Fructus Crataegi 15 g, vinegar prepared Radix Bupleuri 10 g, Radix Curcumae 10 g, Radix Salviae Miltiorrhizae 12 g, Herba Lycopi 12 g, talc 12 g, Radix Glycyrrhizae 2 g), one dose twice per day orally for 12 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid tablet (UAT) 150 mg three times per day for 12 weeks
Number of subjects: 62
Study: 12557834

Group type: COMPARATOR
Intervention: Alfentanil 40 microg kg(‐1) followed by propofol 2 mg kg(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Remifentanil 2 microg kg(‐1) followed by propofol 2 mg kg(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Remifentanil 3 microg kg(‐1) followed by propofol 2 mg kg(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Remifentanil 4 microg kg(‐1) followed by propofol 2 mg kg(‐1)
Number of subjects: 80
Study: 10694780

Group type: EXPERIMENTAL
Intervention: 0.6 % of energy trans alpha‐linolenic acid for 6 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Low trans alpha‐linolenic acid diet for 6 weeks
Number of subjects: 88
Study: 8899093

Group type: EXPERIMENTAL
Intervention: Lansoprazole plus amoxycillin (lansoprazole 30 mg o.m. for 6 or 8 weeks + amoxycillin 500 mg q.d.s. for the first 2 weeks)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Lansoprazole alone (30 mg o.m. for 6 or 8 weeks)
Number of subjects: 119
Study: 1985415

Group type: EXPERIMENTAL
Intervention: High-dosage antioxidants (tocopherol and ascorbate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not taking antioxidants)
Number of subjects: 0
Study: 6630556

Group type: EXPERIMENTAL
Intervention: examiner praise
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: neutral feedback
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: token reinforcement
Number of subjects: 51